Drug Interactions between cholecalciferol / iron polysaccharide and DeWitt's Pain Reliever
This report displays the potential drug interactions for the following 2 drugs:
- cholecalciferol/iron polysaccharide
- DeWitt's Pain Reliever (magnesium salicylate)
Interactions between your drugs
magnesium salicylate cholecalciferol
Applies to: DeWitt's Pain Reliever (magnesium salicylate) and cholecalciferol / iron polysaccharide
GENERALLY AVOID: Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.
MANAGEMENT: Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.
References
- (2001) "Product Information. Rocaltrol (calcitriol)." Roche Laboratories
- (2001) "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical
- (2004) "Product Information. Hectorol (doxercalciferol)." Genzyme Corporation
- (2004) "Product Information. One-Alpha (alfacalcidol)." Pharmel Inc
Drug and food interactions
iron polysaccharide food
Applies to: cholecalciferol / iron polysaccharide
ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.
Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.
MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.
References
- "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
- (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics
magnesium salicylate food
Applies to: DeWitt's Pain Reliever (magnesium salicylate)
GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.
MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.
References
- (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.